openPR Logo
Press release

Murine Double Minute 2 (MDM2) Inhibitor Pipeline Analysis 2024: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Companies by DelveInsight

06-14-2024 08:21 AM CET | Health & Medicine

Press release from: DelveInsight Business Research

Murine Double Minute 2 (MDM2) Inhibitor Pipeline

Murine Double Minute 2 (MDM2) Inhibitor Pipeline

(Albany, USA) As per DelveInsight's assessment, globally, Murine Double Minute 2 (MDM2) Inhibitor pipeline constitutes key companies continuously working towards developing Murine Double Minute 2 (MDM2) Inhibitor treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Murine Double Minute 2 (MDM2) Inhibitor Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Murine Double Minute 2 (MDM2) Inhibitor Market.
The Murine Double Minute 2 (MDM2) Inhibitor Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Request for Sample Report @ https://www.delveinsight.com/sample-request/murine-double-minute-2-mdm2-inhibitor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of the key takeaways from the Murine Double Minute 2 (MDM2) Inhibitor Pipeline Report:
• MDM2 Inhibitor Companies across the globe are diligently working toward developing novel Murine Double Minute 2 (MDM2) Inhibitor treatment therapies with a considerable amount of success over the years.
• Murine Double Minute 2 (MDM2) Inhibitor companies working in the treatment market are Ascentage Pharma, Kartos Therapeutics, Boehringer Ingelheim, Rain Oncology, and others, are developing therapies for the Murine Double Minute 2 (MDM2) Inhibitor treatment
• Emerging Murine Double Minute 2 (MDM2) Inhibitor therapies in the different phases of clinical trials are- APG-115, KRT-232, BI 907828, RAIN-32, and others are expected to have a significant impact on the Murine Double Minute 2 (MDM2) Inhibitor market in the coming years.
• ASTX295, a synthetic small molecule, functions as an antagonist of Murine Double Minute 2 (MDM2). Discovered through collaboration between Astex and the Cancer Research UK Drug Discovery Unit at Newcastle University, Astex holds an exclusive license for the research, development, and commercialization of ASTX295 under its drug discovery alliance agreement with Newcastle University and Cancer Research Technology Limited. ASTX295 is presently undergoing assessment in a Phase 1/2 study involving patients with advanced solid tumors characterized by wild-type p53 to ascertain safety, pharmacokinetics, and preliminary activity. The development of ASTX295 is currently being managed by Taiho Oncology Inc.

Murine Double Minute 2 (MDM2) Inhibitor Overview
Murine Double Minute 2 (MDM2) is an oncogene that plays a critical role in regulating the p53 tumor suppressor protein. MDM2 inhibits p53 by binding to it, promoting its degradation, and blocking its transcriptional activity. Overexpression of MDM2 is associated with various cancers, making it a target for anticancer therapies.
MDM2 inhibitors are a class of drugs designed to block the interaction between MDM2 and p53, thereby restoring the tumor-suppressing function of p53. These inhibitors can potentially trigger cancer cell death and halt tumor growth. Small molecule inhibitors, such as Nutlin-3, AMG 232, and RG7388 (Idasanutlin), have shown promise in preclinical and clinical studies. Nutlin-3, for example, mimics the p53-binding domain and disrupts the MDM2-p53 interaction.
Clinical trials have demonstrated that MDM2 inhibitors can be effective, particularly in tumors with intact p53. These drugs are being investigated for various cancers, including sarcomas, leukemias, and solid tumors. However, challenges such as drug resistance and toxicity need to be addressed to optimize their therapeutic potential. Research continues to refine these inhibitors and explore combination therapies to enhance their efficacy and reduce adverse effects.

Get a Free Sample PDF Report to know more about Murine Double Minute 2 (MDM2) Inhibitor Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/murine-double-minute-2-mdm2-inhibitor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Murine Double Minute 2 (MDM2) Inhibitor Drugs Under Different Phases of Clinical Development Include:
• APG-115: Ascentage Pharma
• KRT-232: Kartos Therapeutics
• BI 907828: Boehringer Ingelheim
• RAIN-32: Rain Oncology

Murine Double Minute 2 (MDM2) Inhibitor Pipeline Therapeutics Assessment
• Murine Double Minute 2 (MDM2) Inhibitor Assessment by Product Type
• Murine Double Minute 2 (MDM2) Inhibitor By Stage and Product Type
• Murine Double Minute 2 (MDM2) Inhibitor Assessment by Route of Administration
• Murine Double Minute 2 (MDM2) Inhibitor By Stage and Route of Administration
• Murine Double Minute 2 (MDM2) Inhibitor Assessment by Molecule Type
• Murine Double Minute 2 (MDM2) Inhibitor by Stage and Molecule Type

DelveInsight's Murine Double Minute 2 (MDM2) Inhibitor Report covers around products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Murine Double Minute 2 (MDM2) Inhibitor product details are provided in the report. Download the Murine Double Minute 2 (MDM2) Inhibitor pipeline report to learn more about the emerging Murine Double Minute 2 (MDM2) Inhibitor therapies at:
https://www.delveinsight.com/sample-request/murine-double-minute-2-mdm2-inhibitor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Murine Double Minute 2 (MDM2) Inhibitor Pipeline Analysis:
The Murine Double Minute 2 (MDM2) Inhibitor pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Murine Double Minute 2 (MDM2) Inhibitor with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Murine Double Minute 2 (MDM2) Inhibitor Treatment.
• Murine Double Minute 2 (MDM2) Inhibitor key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Murine Double Minute 2 (MDM2) Inhibitor Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Murine Double Minute 2 (MDM2) Inhibitor market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Murine Double Minute 2 (MDM2) Inhibitor drugs and therapies-
https://www.delveinsight.com/sample-request/murine-double-minute-2-mdm2-inhibitor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Murine Double Minute 2 (MDM2) Inhibitor Pipeline Market Drivers
• Murine Double Minute 2 (MDM2) Inhibitor, a potentially high value anticancer therapies • Worldwide rise in the number of cancer patients are some of the important factors that are fueling the Murine Double Minute 2 (MDM2) Inhibitor Market.

Murine Double Minute 2 (MDM2) Inhibitor Pipeline Market Barriers
• However, challenges in designing a selective Murine Double Minute 2 (MDM2) Inhibitor, available therapeutics with inherent limitations and other factors are creating obstacles in the Murine Double Minute 2 (MDM2) Inhibitor Market growth.

Scope of Murine Double Minute 2 (MDM2) Inhibitor Pipeline Drug Insight
• Coverage: Global
• Key Murine Double Minute 2 (MDM2) Inhibitor Companies: Ascentage Pharma, Kartos Therapeutics, Boehringer Ingelheim, Rain Oncology, and others
• Key Murine Double Minute 2 (MDM2) Inhibitor Therapies: APG-115, KRT-232, BI 907828, RAIN-32, and others
• Murine Double Minute 2 (MDM2) Inhibitor Therapeutic Assessment: Murine Double Minute 2 (MDM2) Inhibitor current marketed and Murine Double Minute 2 (MDM2) Inhibitor emerging therapies
• Murine Double Minute 2 (MDM2) Inhibitor Market Dynamics: Murine Double Minute 2 (MDM2) Inhibitor market drivers and Murine Double Minute 2 (MDM2) Inhibitor market barriers

Request for Sample PDF Report for Murine Double Minute 2 (MDM2) Inhibitor Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/murine-double-minute-2-mdm2-inhibitor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Murine Double Minute 2 (MDM2) Inhibitor Report Introduction
2. Murine Double Minute 2 (MDM2) Inhibitor Executive Summary
3. Murine Double Minute 2 (MDM2) Inhibitor Overview
4. Murine Double Minute 2 (MDM2) Inhibitor- Analytical Perspective In-depth Commercial Assessment
5. Murine Double Minute 2 (MDM2) Inhibitor Pipeline Therapeutics
6. Murine Double Minute 2 (MDM2) Inhibitor Late Stage Products (Phase II/III)
7. Murine Double Minute 2 (MDM2) Inhibitor Mid Stage Products (Phase II)
8. Murine Double Minute 2 (MDM2) Inhibitor Early Stage Products (Phase I)
9. Murine Double Minute 2 (MDM2) Inhibitor Preclinical Stage Products
10. Murine Double Minute 2 (MDM2) Inhibitor Therapeutics Assessment
11. Murine Double Minute 2 (MDM2) Inhibitor Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Murine Double Minute 2 (MDM2) Inhibitor Key Companies
14. Murine Double Minute 2 (MDM2) Inhibitor Key Products
15. Murine Double Minute 2 (MDM2) Inhibitor Unmet Needs
16 . Murine Double Minute 2 (MDM2) Inhibitor Market Drivers and Barriers
17. Murine Double Minute 2 (MDM2) Inhibitor Future Perspectives and Conclusion
18. Murine Double Minute 2 (MDM2) Inhibitor Analyst Views
19. Appendix
20. About DelveInsight

Trending Reports:
• Biochips Market: https://www.delveinsight.com/report-store/biochips-market
• Bone Anchored Hearing Systems Market: https://www.delveinsight.com/report-store/bone-anchored-hearing-systems-market
• Minimal Residual Disease Market: https://www.delveinsight.com/report-store/minimal-residual-disease-market
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Pain Management Devices Market: https://www.delveinsight.com/report-store/pain-management-devices-market
• Pressure Ulcers Market Size: https://www.delveinsight.com/report-store/pressure-ulcers-market
• Blood Glucose Monitoring Systems Market: https://www.delveinsight.com/report-store/blood-glucose-monitoring-systems-market
• Dysthymia Market: https://www.delveinsight.com/report-store/major-depressive-disorder-market
• Osteoarthritis Market: https://www.delveinsight.com/report-store/knee-osteoarthritis-market
• Vascular Access Devices Market: https://www.delveinsight.com/report-store/vascular-access-device-market
• Hearing Aid Devices Market: https://www.delveinsight.com/report-store/hearing-aid-devices-market
• Lymphocytopenia Market: https://www.delveinsight.com/report-store/lymphocytopenia-market
• Gaucher Disease Market: https://www.delveinsight.com/report-store/gauchers-disease-market
• Defibrillators Market: https://www.delveinsight.com/report-store/defibrillator-market
• Human Papilomavirus Market: https://www.delveinsight.com/report-store/human-papillomavirus-hpv-market
• Bradycardia Treatment Devices Market: https://www.delveinsight.com/report-store/electrophysiology-devices-market
• Asphyxia Market: https://www.delveinsight.com/report-store/asphyxia-epidemiology-forecast
• Abetalipoproteinemia Market: https://www.delveinsight.com/report-store/abetalipoproteinemia-market
• Acute Agitation And Aggression Market: https://www.delveinsight.com/report-store/acute-agitation-and-aggression-market
• Alpha-mannosidosis Market: https://www.delveinsight.com/report-store/alpha-mannosidosis-market
• Bartonellosis Market: https://www.delveinsight.com/report-store/bartonellosis-market
• Blood Gas And Electrolyte Analyzers Market: https://www.delveinsight.com/report-store/blood-gas-and-electrolyte-analyzers-market
• Cellulitis Market: https://www.delveinsight.com/report-store/cellulitis-market
• Ocular Motility Disturbance Market: https://www.delveinsight.com/report-store/ocular-motility-disturbance-market
• Vitamin A Deficiency Market: https://www.delveinsight.com/report-store/vitamin-a-deficiency-market

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/asco-conference-coverage

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Murine Double Minute 2 (MDM2) Inhibitor Pipeline Analysis 2024: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Companies by DelveInsight here

News-ID: 3538788 • Views:

More Releases from DelveInsight Business Research

Myasthenia Gravis Pipeline Analysis, 2024 Updates | Latest FDA, EMA, and PMDA Approvals | Alpine Immune Science, Toleranzia, Cabaletta Bio, Rallybio, Alexion Pharmaceuticals, Takeda
Myasthenia Gravis Pipeline Analysis, 2024 Updates | Latest FDA, EMA, and PMDA Ap …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Myasthenia Gravis pipeline constitutes 20+ key companies continuously working towards developing 22+ Myasthenia Gravis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. The Myasthenia Gravis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also
Keratoconus Market to Show Remarkable Growth Trends from 2023 to 2032, DelveInsight Reports | Glaukos Corporation, iVeena Delivery Systems, Ocular Therapeutix
Keratoconus Market to Show Remarkable Growth Trends from 2023 to 2032, DelveInsi …
DelveInsight's "Keratoconus Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Keratoconus, historical and forecasted epidemiology as well as the Keratoconus market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the Keratoconus market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Keratoconus Market Forecast https://www.delveinsight.com/sample-request/keratoconus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Some of the key facts of the Keratoconus
Tenosynovial Giant Cell Tumors Market Expected to Experience Major Growth by 2034, According to DelveInsight | Daiichi Sankyo Co., Ltd., Deciphera Pharmaceuticals, Abbisko Therapeutics, AmMax Bio, Inc., SynOx Therapeutics
Tenosynovial Giant Cell Tumors Market Expected to Experience Major Growth by 203 …
DelveInsight's "Tenosynovial Giant Cell Tumors Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Tenosynovial Giant Cell Tumors, historical and forecasted epidemiology as well as the Tenosynovial Giant Cell Tumors market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the Tenosynovial Giant Cell Tumors market outlook, drug uptake, treatment scenario and epidemiology trends, Click
Psoriatic Arthritis Market Forecasted to Surge in Coming Years, 2023-2032 Analysis by DelveInsight | AbbVie, Novartis, Janssen Research, Sun Pharma, Bristol-Myers Squibb, UCB Biopharma, Affibody AB, Ventyx Biosciences, Aclaris Therapeutics
Psoriatic Arthritis Market Forecasted to Surge in Coming Years, 2023-2032 Analys …
DelveInsight's "Psoriatic Arthritis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Psoriatic Arthritis, historical and forecasted epidemiology as well as the Psoriatic Arthritis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the Psoriatic Arthritis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Psoriatic Arthritis Market Forecast https://www.delveinsight.com/sample-request/psoriatic-arthritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Some of the

All 5 Releases


More Releases for MDM2

Want to know positive clinical results of MDM2 Protein Inhibitors Therapeutics? …
MDM2 protein are powerful oncogene which is overexpressed in various cancers, including breast cancer and sarcoma. There are many small molecule drug candidates that are being developed as MDM2 protein inhibitors as monotherapy or combination therapy for the treatment of various cancers. Combination therapies are more effective than monotherapy in certain cases. The therapeutic strategies aim at blocking MDM2 expression, blocking the physical interaction between MDM2 and p53, modulating the
MDM2 Protein Inhibitors Therapeutics, Clinical Trials & Results, Pipeline Analys …
MDM2 protein are powerful oncogene which is overexpressed in various cancers, including breast cancer and sarcoma. There are many small molecule drug candidates that are being developed as MDM2 protein inhibitors as monotherapy or combination therapy for the treatment of various cancers. Combination therapies are more effective than monotherapy in certain cases. The therapeutic strategies aim at blocking MDM2 expression, blocking the physical interaction between MDM2 and p53, modulating the
Liposarcoma Therapeutics, Clinical Results, Designations, Collaborations, Licens …
Liposarcoma is a type of tumour that arises from fat tissues in thighs, legs, abdomen, and retroperitoneum. Liposarcoma is also considered as malignant tumour because it spread to surrounding organs. According to the World Health Organization, liposarcoma is characterized into five types including, myxoid, well differentiated, dedifferentiated, round cell, and pleomorphic. Liposarcoma is generally observed as painless enlarged mass. Access Report Overview: https://www.psmarketresearch.com/market-analysis/liposarcoma-therapeutics-pipeline-analysis It affects men and women equally. Well
In Depth Research on Oncogene Inhibitors Market & Pipeline Insight 2015
" Oncogene Inhibitors Market & Pipeline Insight 2015" Report Highlight: * Global Oncogene Inhibitors Market Overview * Oncogene Inhibitors Pipeline by Company, Indication & Phase * Oncogene Inhibitors Pipeline: 185 Drugs * Majority Oncogene Inhibitors in Preclinical Phase: 105 Drugs * Proto Oncogene Protein c met Inhibitors Pipeline: 42 Drugs * Proto Oncogene Protein c-akt Inhibitors: 39 Drugs * Marketed Oncogene Inhibitors: 22 Drugs * Marketed Proto-Oncogene Protein c-bcl-2 Inhibitors: 8 Drugs For Report Sample Contact: neeraj@kuickresearch.com
In Depth Research on Cancer Targeted Therapy Market & Clinical Insight 2015
“Cancer Targeted Therapy Market & Clinical Insight” Report Highlight: * Introduction & Categorization of Cancer Targeted Therapies * Mechanism of Cancer Targeted Tyrosine Kinase, Vaccines, Oncogenes Inhibitors, Monoclonal Antibodies * Cancer Targeted Therapy Clinical Pipeline by Company, Indication & Phase * Clinical Insight on More Than 1200 Cancer Targeted Therapies in Pipeline * Clinical Insight & Patent Analysis of Marketed Cancer Targeted Therapies * Global Cancer Targeted Therapeutics Market Dynamics * Future Prospects of Cancer Targeted
Oncogene Inhibitors Market Sales Revenue Clinical Trials Pipeline Report 2015
Oncogenomics is an emerging field that involves screening of genes that may be involved in cancer development. Human genome consists of 23 chromosomal pairs, approximately 20,000- 25,000 genes and 3,234.83 Mb genome size. Oncogene addiction is a phenomenon in which cancer could be checked by deactivating single oncogene. Proto-onco genes are main target of investigators because they may convert into oncogenes at any stage of life. Sequence level similarity and